119 related articles for article (PubMed ID: 11271495)
1. Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine.
Kovárová H; Hajdúch M; Korínková G; Halada P; Krupicková S; Gouldsworthy A; Zhelev N; Strnad M
Electrophoresis; 2000 Nov; 21(17):3757-64. PubMed ID: 11271495
[TBL] [Abstract][Full Text] [Related]
2. Application of proteomics in the search for novel proteins associated with the anti-cancer effect of the synthetic cyclin-dependent kinases inhibitor, bohemine.
Kovarova H; Halada P; Man P; Dzubak P; Hajduch M
Technol Cancer Res Treat; 2002 Aug; 1(4):247-56. PubMed ID: 12625783
[TBL] [Abstract][Full Text] [Related]
3. Protein fingerprints of anti-cancer effects of cyclin-dependent kinase inhibition: identification of candidate biomarkers using 2-D liquid phase separation coupled to mass spectrometry.
Skalnikova H; Halada P; Dzubak P; Hajduch M; Kovarova H
Technol Cancer Res Treat; 2005 Aug; 4(4):447-54. PubMed ID: 16029063
[TBL] [Abstract][Full Text] [Related]
4. Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity.
Trávnícek Z; Krystof V; Sipl M
J Inorg Biochem; 2006 Feb; 100(2):214-25. PubMed ID: 16386795
[TBL] [Abstract][Full Text] [Related]
5. The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors.
Korinkova G; Cwiertka K; Paprskarova M; Dzubak P; Hajduch M
Neoplasma; 2010; 57(2):161-9. PubMed ID: 20099981
[TBL] [Abstract][Full Text] [Related]
6. Mixed ligand complexes of platinum(II) and palladium(II) with cytokinin-derived compounds Bohemine and Olomoucine: X-ray structure of [Pt(BohH+-N7)Cl(3)].9/5H2O [Boh=6-(benzylamino)-2-[(3-(hydroxypropyl)-amino]-9-isopropylpurine, Bohemine].
Trávnícek Z; Malon M; Zatloukal M; Dolezal K; Strnad M; Marek J
J Inorg Biochem; 2003 Apr; 94(4):307-16. PubMed ID: 12667701
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological activity of olomoucine II.
Krystof V; Lenobel R; Havlícek L; Kuzma M; Strnad M
Bioorg Med Chem Lett; 2002 Nov; 12(22):3283-6. PubMed ID: 12392733
[TBL] [Abstract][Full Text] [Related]
8. Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines.
Mad'arová J; Lukesová M; Hlobilková A; Strnad M; Vojtesek B; Lenobel R; Hajdúch M; Murray PG; Perera S; Kolár Z
Mol Pathol; 2002 Aug; 55(4):227-34. PubMed ID: 12147712
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.
Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Giocanti N; Sadri R; Favaudon V
Bioorg Med Chem; 1999 Jul; 7(7):1281-93. PubMed ID: 10465404
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM
Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P
Clin Cancer Res; 2005 Jul; 11(13):4875-87. PubMed ID: 16000586
[TBL] [Abstract][Full Text] [Related]
12. Cancer drug-resistance and a look at specific proteins: Rho GDP-dissociation inhibitor 2, Y-box binding protein 1, and HSP70/90 organizing protein in proteomics clinical application.
Skalnikova H; Martinkova J; Hrabakova R; Halada P; Dziechciarkova M; Hajduch M; Gadher SJ; Hammar A; Enetoft D; Ekefjard A; Forsstrom-Olsson O; Kovarova H
J Proteome Res; 2011 Feb; 10(2):404-15. PubMed ID: 21067243
[TBL] [Abstract][Full Text] [Related]
13. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases.
Abraham RT; Acquarone M; Andersen A; Asensi A; Bellé R; Berger F; Bergounioux C; Brunn G; Buquet-Fagot C; Fagot D
Biol Cell; 1995; 83(2-3):105-20. PubMed ID: 7549905
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases.
Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L
Bioorg Med Chem Lett; 1998 Apr; 8(7):793-8. PubMed ID: 9871543
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
16. Meiotic inhibition with different cyclin-dependent kinase inhibitors in bovine oocytes and its effects on maturation and embryo development.
Adona PR; Lima Verde Leal C
Zygote; 2004 Aug; 12(3):197-204. PubMed ID: 15521709
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological activities of C-2, N-9 substituted 6-benzylaminopurine derivatives as cyclin-dependent kinase inhibitor.
Oh CH; Lee SC; Lee KS; Woo ER; Hong CY; Yang BS; Baek DJ; Cho JH
Arch Pharm (Weinheim); 1999 Jun; 332(6):187-90. PubMed ID: 10399486
[TBL] [Abstract][Full Text] [Related]
18. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
[TBL] [Abstract][Full Text] [Related]
19. Activation of bovine oocytes by specific inhibition of cyclin-dependent kinases.
Alberio R; Kubelka M; Zakhartchenko V; Hajdúch M; Wolf E; Motlik J
Mol Reprod Dev; 2000 Apr; 55(4):422-32. PubMed ID: 10694750
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors.
Atienza C; Elliott MJ; Dong YB; Yang HL; Stilwell A; Liu TJ; McMasters KM
Int J Mol Med; 2000 Jul; 6(1):55-63. PubMed ID: 10851267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]